Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
1.
Am J Hypertens ; 33(7): 610-619, 2020 07 18.
Article in English | MEDLINE | ID: mdl-32242611

ABSTRACT

BACKGROUND: Oxidative stress is known to be associated with the development of diabetes. Cinnamaldehyde (CA) is a spice compound in cinnamon that enhances the antioxidant defense against reactive oxygen species (ROS) by activating nuclear factor erythroid-related factor 2 (Nrf2), which has been shown to have a cardioprotection effect. However, the relationship between CA and Nrf2 in diabetic vascular complications remains unclear. METHODS: Leptin receptor-deficient (db/db) mice were fed normal chow or diet containing 0.02% CA for 12 weeks. The vascular tone, blood pressure, superoxide level, nitric oxide (NO) production, renal morphology, and function were measured in each group. RESULTS: CA remarkably inhibited ROS generation, preserved NO production, increased phosphorylated endothelial nitric oxide synthase (p-eNOS), attenuated the upregulation of nitrotyrosine, P22 and P47 in aortas of db/db mice, and apparently ameliorated the elevation of type IV collagen, TGF-ß1, P22, and P47 in kidney of db/db mice. Feeding with CA improved endothelium-dependent relaxation of aortas and mesenteric arteries, and alleviated the remodeling of mesenteric arteries in db/db mice. Additionally, dietary CA ameliorated glomerular fibrosis and renal dysfunction in diabetic mice. Nrf2 and its targeted genes heme oxygenase-1 (HO-1) and quinone oxidoreductase-1 (NQO-1) were slightly increased in db/db mice and further upregulated by CA. However, these protective effects of CA were reversed in Nrf2 downregulation mice. CONCLUSIONS: A prolonged diet of CA protects against diabetic vascular dysfunction by inhibiting oxidative stress through activating of Nrf2 signaling pathway in db/db mice.


Subject(s)
Acrolein/analogs & derivatives , Diabetes Mellitus, Experimental/complications , Diabetic Angiopathies/prevention & control , Flavoring Agents/therapeutic use , NF-E2-Related Factor 2/metabolism , Acrolein/pharmacology , Acrolein/therapeutic use , Animals , Aorta/drug effects , Aorta/metabolism , Diabetes Mellitus, Experimental/metabolism , Drug Evaluation, Preclinical , Flavoring Agents/pharmacology , Kidney/drug effects , Male , Mice, Inbred C57BL , Nitric Oxide/metabolism , Oxidative Stress/drug effects , Reactive Oxygen Species/metabolism , TRPA1 Cation Channel/metabolism
2.
Pharmacology ; 105(9-10): 531-540, 2020.
Article in English | MEDLINE | ID: mdl-32259820

ABSTRACT

Atherosclerosis (AS) is a chronical pathological process of the arterial narrows due to the AS plaque formation. The aim of this study was to explore the therapeutic effect and the underlying mechanism of Floralozone on experimental atherosclerotic model rats. Experimental atherosclerotic model rats were induced by the right carotid artery balloon injury and intraperitoneal injection of vitamin D3 in rats after 4 weeks high-fat diet. The results exhibited that Floralozone could ameliorate vascular injury and vasorelaxation of descending aortas and increase the superoxide dismutase activity and the expression of sphingosine 1-phosphate (S1P) 1 and reduce the intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, interleukin (IL)-1, IL-6 level, and the malondialdehyde activity in experimental atherosclerotic rats. However, Fingolimod, an S1P1 inhibitor, could reverse these Floralozone effects in experimental atherosclerotic rats. Our results indicated that Floralozone could inhibit the atherosclerotic plaque formation and improves arterial stenosis and reduces endothelial dysfunction in experimental atherosclerotic rats, which might be involved with S1P1 enhancement.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Atherosclerosis/drug therapy , Atherosclerosis/metabolism , Flavoring Agents/pharmacology , Lysophospholipids/metabolism , Plant Extracts/pharmacology , Sphingosine-1-Phosphate Receptors/metabolism , Sphingosine/analogs & derivatives , Animals , Anti-Inflammatory Agents/therapeutic use , Aromatherapy , Atherosclerosis/etiology , Balloon Occlusion/adverse effects , Carotid Arteries/diagnostic imaging , Carotid Arteries/drug effects , Diet, High-Fat/adverse effects , Disease Models, Animal , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Endothelium, Vascular/physiopathology , Flavoring Agents/therapeutic use , Male , Plant Extracts/therapeutic use , Plaque, Atherosclerotic/drug therapy , Plaque, Atherosclerotic/etiology , Plaque, Atherosclerotic/pathology , Rats , Rats, Sprague-Dawley , Retinal Artery/diagnostic imaging , Retinal Artery/drug effects , Sphingosine/metabolism , Vasodilation/drug effects
3.
Molecules ; 23(9)2018 Aug 23.
Article in English | MEDLINE | ID: mdl-30142916

ABSTRACT

The purpose of this research was to evaluate whether maltol could protect from hepatic injury induced by carbon tetrachloride (CCl4) in vivo by inhibition of apoptosis and inflammatory responses. In this work, maltol was administered at a level of 100 mg/kg for 15 days prior to exposure to a single injection of CCl4 (0.25%, i.p.). The results clearly indicated that the intrapulmonary injection of CCl4 resulted in a sharp increase in serum aspartate transaminase (AST) and alanine transaminase (ALT) activities, tumor necrosis factor-α (TNF-α), irreducible nitric oxide synthase (iNOS), nuclear factor-kappa B (NF-κB) and interleukin-1ß (IL-1ß) levels. Histopathological examination demonstrated severe hepatocyte necrosis and the destruction of architecture in liver lesions. Immunohistochemical staining and western blot analysis suggested an accumulation of iNOS, NF-κB, IL-1ß and TNF-α expression. Maltol, when administered to mice for 15 days, can significantly improve these deleterious changes. In addition, TUNEL and Hoechst 33258 staining showed that a liver cell nucleus of a model group diffused uniform fluorescence following CCl4 injection. Maltol pretreatment groups did not show significant cell nuclear condensation and fragmentation, indicating that maltol inhibited CCl4-induced cell apoptosis. By evaluating the liver catalase (CAT), glutathione (GSH), superoxide dismutase (SOD) activity, and further using a single agent to evaluate the oxidative stress in CCl4-induced hepatotoxicity by immunofluorescence staining, maltol dramatically attenuated the reduction levels of hepatic CAT, GSH and SOD, and the over-expression levels of CYP2E1 and HO-1. In the mouse model of CCl4-induced liver injury, we have demonstrated that the inflammatory responses were inhibited, the serum levels of ALT and AST were reduced, cell apoptosis was suppressed, and liver injury caused by CCl4 was alleviated by maltol, demonstrating that maltol may be an efficient hepatoprotective agent.


Subject(s)
Carbon Tetrachloride/toxicity , Chemical and Drug Induced Liver Injury/drug therapy , Liver/drug effects , Liver/injuries , Pyrones/therapeutic use , Animals , Apoptosis/drug effects , Catalase/metabolism , Chemical and Drug Induced Liver Injury/immunology , Chemical and Drug Induced Liver Injury/metabolism , Flavoring Agents/therapeutic use , Glutathione/metabolism , Immunohistochemistry , Inflammation/metabolism , Male , Mice , Oxidative Stress/drug effects , Superoxide Dismutase/metabolism
4.
Indian J Pediatr ; 84(10): 739-744, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28523393

ABSTRACT

OBJECTIVES: To evaluate the clinical efficacy of masking the odor of inhalational agents using fruit flavors on the anxiety behavior and compliance of children for inhalational induction. METHODS: A prospective randomized double blind, placebo controlled study was conducted on 60 unpremedicated children in the age group of 4-12 y. Thirty children received anesthetic masks smeared with a flavor of child's choice while the other 30 children were induced using masks without flavor. Anxiety was assessed using modified Yale Pre-operative Anxiety Scale (mYPAS) in the pre-op room and during inhalational induction. Mask acceptance was graded by Induction Compliance Checklist (ICC). The cost-effectiveness of flavored anesthetic masks was compared to that of commercially available pre-scented masks. RESULTS: The baseline anxiety in the two groups was comparable. The number of children demonstrating high levels of anxiety at anesthetic induction was similar in flavored and non-flavored mask groups (p 0.45). The compliance to mask induction was also equally good (p 0.99). The authors found significant difference in the cost of flavored mask (INR 56.45 per mask) as compared to commercially available pre-scented masks (INR 660 per mask). CONCLUSIONS: The authors observed a placebo effect that reduced the pre-op anxiety in the control group which probably made the quality of induction equivalent with flavored and non-flavored masks. Therefore, using a flavored anesthetic mask is cost-effective than using a commercially available pre-scented mask.


Subject(s)
Anesthesia, Inhalation/methods , Flavoring Agents/therapeutic use , Anesthesia, Inhalation/economics , Anesthesia, Inhalation/instrumentation , Anxiety/prevention & control , Child , Child, Preschool , Cost-Benefit Analysis , Double-Blind Method , Female , Humans , Male , Prospective Studies
5.
J Med Food ; 18(6): 706-10, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25675137

ABSTRACT

Antiobesity effects of bamboo salt (BS) were evaluated compared with those of purified salt and solar salt by oral administration in a diet-induced obesity model using C57BL/6 mice. Compared with other salts, BS, especially nine times baked BS (BS-9×), significantly reduced body weight, food efficiency ratio, and weights of epididymal adipose tissue and liver in high-fat diet-fed mice. Furthermore, BS suppressed the expression of adipogenic factors, such as CCAAT/enhancer binding protein alpha (C/EBPα), peroxisome proliferator-activated receptor gamma (PPARγ), and sterol regulatory element-binding protein 1c (SREBP-1c). Therefore, BS may suppress obesity by downregulating adipogenesis.


Subject(s)
Adipogenesis/drug effects , Adipose Tissue/drug effects , Flavoring Agents/therapeutic use , Food Handling , Minerals/therapeutic use , Obesity/diet therapy , Sasa , Adipose Tissue/metabolism , Animals , Body Weight/drug effects , CCAAT-Enhancer-Binding Protein-alpha/metabolism , Diet, High-Fat , Down-Regulation , Flavoring Agents/pharmacology , Liver/drug effects , Mice , Mice, Inbred C57BL , Minerals/pharmacology , Obesity/etiology , Obesity/metabolism , Sterol Regulatory Element Binding Protein 1/metabolism
6.
Eur J Pharmacol ; 740: 192-9, 2014 Oct 05.
Article in English | MEDLINE | ID: mdl-25046838

ABSTRACT

Methyl cinnamate (MC) is a safe flavoring agent useful to food industry. Although chemically analog to tyrosine kinase inhibitors, there is little information regarding its biological actions. Here, we aimed at assessing the MC effects on gastrointestinal contractility and the putative involvement of tyrosine kinase in the mediation of these effects. Isometric contractions were recorded in rat isolated strips from stomach, duodenum and colon segments. In gastric strips, MC (3-3000 µM) showed antispasmodic effects against carbachol-induced contractions, which remained unchanged by either l-NAME or tetraethylammonium pretreatment and occurred with potency similar to that obtained against contractions evoked by potassium or U-46619. In colon strips, MC was four times more potent than in gastric ones. MC and the positive control genistein inhibited phasic contractions induced by acetylcholine in Ca2+-free medium, an effect fully prevented by sodium orthovanadate. Both MC and genistein decreased the spontaneous contractions of duodenal strips and shortened the time necessary for gastric fundic tissues to reach 50% of maximal relaxation. In freshly isolated colon myocytes, MC decreased the basal levels of cytoplasmic Ca2+, but not the potassium-elicited cytoplasmic Ca2+ elevation. Colon strips obtained from rats subjected to intracolonic acetic acid instillation showed reduced contractility to potassium, which was partially recovered in MC-treated rats. Inhibitory effect of nifedipine against cholinergic contractions, blunted in acetic acid-induced colitis, was also recovered in MC-treated rats. In conclusion, MC inhibited the gastrointestinal contractility with a probable involvement of tyrosine kinase pathways. In vivo, it was effective to prevent the deleterious effects of colitis resulting from acetic acid injury.


Subject(s)
Cinnamates/pharmacology , Colon/drug effects , Duodenum/drug effects , Flavoring Agents/pharmacology , Parasympatholytics/pharmacology , Stomach/drug effects , Acetic Acid , Animals , Calcium/metabolism , Calcium Channel Blockers/pharmacology , Carbachol , Cinnamates/therapeutic use , Colitis/chemically induced , Colitis/drug therapy , Colitis/physiopathology , Colon/physiology , Duodenum/physiology , Flavoring Agents/therapeutic use , In Vitro Techniques , Male , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , Muscle, Smooth/physiology , Nifedipine/pharmacology , Parasympatholytics/therapeutic use , Potassium Chloride/pharmacology , Protein-Tyrosine Kinases/antagonists & inhibitors , Protein-Tyrosine Kinases/physiology , Rats, Wistar , Stomach/physiology
7.
Naunyn Schmiedebergs Arch Pharmacol ; 387(4): 355-65, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24337826

ABSTRACT

Geraniol is an acyclic monoterpene alcohol commonly used as a flavoring agent. The present study was undertaken to investigate antiulcerogenic effects of geraniol and to determine the possible mechanisms involved in this action. In the model of the ethanol-induced ulcer, treatment of rats with geraniol by oral route significantly inhibited gastric lesions by 70 % (7.50 mg/kg) to 99 % (200 mg/kg). Analysis of the gastric tissue of rats treated with geraniol (7.50 mg/kg) revealed that total glutathione content levels (GSH) increased and levels of myeloperoxidase (MPO) decreased in the gastric mucosa. Oral treatment with geraniol significantly decreased the number of ulcerative lesions induced by ischemia/reperfusion injury by 71 % and the duodenal ulcers induced by cysteamine by 68 %. The action of geraniol was mediated by the activation of defensive mucosa-protective factors such as the nitric oxide (NO) pathway, endogenous prostaglandins, increased mucus production, increased sulfhydryl compounds, antioxidant properties and the stimulation of calcitonin gene-related peptide (CGRP) release through the activation of transient receptor potential vanilloid (TRPV). The multifaceted gastroprotective mechanisms of geraniol represent a promising option for the treatment of gastric and duodenal mucosa injury.


Subject(s)
Anti-Ulcer Agents/therapeutic use , Duodenal Ulcer/drug therapy , Flavoring Agents/therapeutic use , Stomach Ulcer/drug therapy , Terpenes/therapeutic use , Acyclic Monoterpenes , Animals , Anti-Ulcer Agents/pharmacology , Cysteamine , Duodenal Ulcer/etiology , Duodenal Ulcer/pathology , Duodenum/drug effects , Duodenum/pathology , Ethanol , Flavoring Agents/pharmacology , Gastric Mucosa/metabolism , Glutathione/metabolism , Male , Mucus/metabolism , Nitric Oxide/metabolism , Peroxidase/metabolism , Pylorus/surgery , Rats , Rats, Wistar , Reperfusion Injury , Stomach/drug effects , Stomach/pathology , Stomach Ulcer/chemically induced , Stomach Ulcer/metabolism , Stomach Ulcer/pathology , Terpenes/pharmacology
8.
Br J Nutr ; 109(3): 394-401, 2013 Feb 14.
Article in English | MEDLINE | ID: mdl-22717234

ABSTRACT

Plant-based whole foods provide thousands of bioactive metabolites to the human diet that reduce the risk of developing chronic diseases. ß-Caryophyllene (CAR) is a common constituent of the essential oil of numerous plants, vegetables, fruits and medicinal herbs, and has been used as a flavouring agent since the 1930 s. Here, we report the antioxidant activity of CAR, its protective effect on liver fibrosis and its inhibitory capacity on hepatic stellate cell (HSC) activation. CAR was tested for the inhibition of lipid peroxidation and as a free radical scavenger. CAR had higher inhibitory capacity on lipid peroxidation than probucol, α-humulene and α-tocopherol. Also, CAR showed high scavenging activities against hydroxyl radical and superoxide anion. The activity of 5-lipoxygenase, an enzyme that actively participates in fibrogenesis, was significantly inhibited by CAR. Carbon tetrachloride-treated rats received CAR at 2, 20 and 200 mg/kg. CAR significantly improved liver structure, and reduced fibrosis and the expression of Col1a1, Tgfb1 and Timp1 genes. Oxidative stress was used to establish a model of HSC activation with overproduction of extracellular matrix proteins. CAR (1 and 10 µm) increased cell viability and significantly reduced the expression of fibrotic marker genes. CAR, a sesquiterpene present in numerous plants and foods, is as a natural antioxidant that reduces carbon tetrachloride-mediated liver fibrosis and inhibits hepatic cell activation.


Subject(s)
Antioxidants/therapeutic use , Carbon Tetrachloride Poisoning/prevention & control , Dietary Supplements , Hepatic Stellate Cells/metabolism , Liver/metabolism , Sesquiterpenes/therapeutic use , Animals , Antioxidants/administration & dosage , Antioxidants/metabolism , Antioxidants/pharmacology , Arachidonate 5-Lipoxygenase/chemistry , Arachidonate 5-Lipoxygenase/metabolism , Carbon Tetrachloride Poisoning/metabolism , Carbon Tetrachloride Poisoning/pathology , Cell Line , Cell Survival/drug effects , Female , Flavoring Agents/administration & dosage , Flavoring Agents/metabolism , Flavoring Agents/therapeutic use , Free Radical Scavengers/administration & dosage , Free Radical Scavengers/metabolism , Free Radical Scavengers/therapeutic use , Hepatic Stellate Cells/drug effects , Hepatic Stellate Cells/enzymology , Lipid Peroxidation/drug effects , Lipoxygenase Inhibitors/administration & dosage , Lipoxygenase Inhibitors/metabolism , Lipoxygenase Inhibitors/therapeutic use , Liver/drug effects , Liver/pathology , Monocyclic Sesquiterpenes , Oxidative Stress/drug effects , Polycyclic Sesquiterpenes , Probucol/pharmacology , Probucol/therapeutic use , Random Allocation , Rats , Rats, Wistar , Sesquiterpenes/administration & dosage , Sesquiterpenes/metabolism , alpha-Tocopherol/metabolism , alpha-Tocopherol/therapeutic use
9.
Head Neck ; 35(8): 1124-31, 2013 Aug.
Article in English | MEDLINE | ID: mdl-22907789

ABSTRACT

BACKGROUND: Treatment for head and neck cancer can reduce peripheral sensory input and impair oropharyngeal swallow. This study examined the effect of enhanced bolus flavor on liquid swallows in these patients. METHODS: Fifty-one patients treated for head and neck cancer with chemoradiation or surgery and 64 healthy adult control subjects served as subjects. All were randomized to receive sour, sweet, or salty bolus flavor. Patients were evaluated at 7-10 days, 1 month, and 3 months after completion of tumor treatment. Control subjects received 1 assessment. RESULTS: All bolus flavors affected oropharyngeal swallow; sour flavor significantly shortened pharyngeal transit time across all evaluations. CONCLUSIONS: Sour flavor influenced the swallow of patients treated for head and neck cancer, as well as that of control subjects in a manner similar to those with neurologic impairment observed in an earlier study. Sour flavor may improve the speed of pharyngeal transit regardless of whether a patient has suffered peripheral or central sensory damage.


Subject(s)
Deglutition Disorders/physiopathology , Deglutition Disorders/therapy , Flavoring Agents/therapeutic use , Head and Neck Neoplasms/complications , Head and Neck Neoplasms/physiopathology , Taste , Adult , Aged , Cohort Studies , Female , Head and Neck Neoplasms/therapy , Humans , Male , Middle Aged , Oropharynx/physiopathology , Xerostomia/etiology , Xerostomia/physiopathology
11.
J Food Sci ; 77(1): M80-5, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22132793

ABSTRACT

UNLABELLED: A previously characterized rice hull smoke extract (RHSE) was tested for bactericidal activity against Salmonella Typhimurium using the disc-diffusion method. The minimum inhibitory concentration (MIC) value of RHSE was 0.822% (v/v). The in vivo antibacterial activity of RHSE (1.0%, v/v) was also examined in a Salmonella-infected Balb/c mouse model. Mice infected with a sublethal dose of the pathogens were administered intraperitoneally a 1.0% solution of RHSE at four 12-h intervals during the 48-h experimental period. The results showed that RHSE inhibited bacterial growth by 59.4%, 51.4%, 39.6%, and 28.3% compared to 78.7%, 64.6%, 59.2%, and 43.2% inhibition with the medicinal antibiotic vancomycin (20 mg/mL). By contrast, 4 consecutive administrations at 12-h intervals elicited the most effective antibacterial effect of 75.0% and 85.5% growth reduction of the bacteria by RHSE and vancomycin, respectively. The combination of RHSE and vancomycin acted synergistically against the pathogen. The inclusion of RHSE (1.0% v/w) as part of a standard mouse diet fed for 2 wk decreased mortality of 10 mice infected with lethal doses of the Salmonella. Photomicrographs of histological changes in liver tissues show that RHSE also protected the liver against Salmonella-induced pathological necrosis lesions. These beneficial results suggest that the RHSE has the potential to complement wood-derived smokes as antimicrobial flavor formulations for application to human foods and animal feeds. PRACTICAL APPLICATION: The new antimicrobial and anti-inflammatory rice hull derived liquid smoke has the potential to complement widely used wood-derived liquid smokes as an antimicrobial flavor and health-promoting formulation for application to foods.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Food Preservatives/therapeutic use , Oryza/chemistry , Plant Extracts/therapeutic use , Salmonella Infections/drug therapy , Salmonella typhimurium/drug effects , Smoke/analysis , Administration, Oral , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacology , Drug Synergism , Drug Therapy, Combination , Female , Flavoring Agents/administration & dosage , Flavoring Agents/pharmacology , Flavoring Agents/therapeutic use , Food Preservatives/administration & dosage , Food Preservatives/pharmacology , Immunity, Cellular/drug effects , Injections, Intraperitoneal , Liver/drug effects , Liver/microbiology , Liver/pathology , Mice , Mice, Inbred BALB C , Plant Epidermis/chemistry , Plant Extracts/administration & dosage , Plant Extracts/pharmacology , Salmonella Infections/immunology , Salmonella Infections/microbiology , Salmonella Infections/pathology , Seeds/chemistry , Specific Pathogen-Free Organisms , Survival Analysis , Vancomycin/pharmacology , Vancomycin/therapeutic use
13.
Addict Behav ; 35(11): 955-60, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20598808

ABSTRACT

Many smokers relapse during cessation attempts due to increases in negative affect. Previous research has shown that chewing confectionary chewing gum appears to lessen the severity of acute nicotine withdrawal symptoms and help individuals who are trying to reduce smoking in part due to the flavor of the gum chewed. The current study compared the effects of three flavored gums to a No Gum Control during 48-hour cessation periods for young dependent smokers. Forty-nine smokers participated in three experimental conditions (peppermint, vanilla, and baked apple cardamom flavored gum) as well as a No Gum Control across four weeks while abstaining from smoking for 48-hours each week. Compared to the No Gum Control, participants in the Gum conditions reported lower levels of anxiety, dysphoria, and tension. Vanilla and baked apple cardamom flavored gum resulted in lower levels of negative affect while peppermint flavored gum was not different from the No Gum Control. These findings indicate that some flavors of gum are effective in reducing the negative affect associated with nicotine withdrawal and may serve as a valuable tool in helping smokers quit.


Subject(s)
Affect , Chewing Gum , Flavoring Agents/therapeutic use , Smoking Cessation/psychology , Substance Withdrawal Syndrome/prevention & control , Case-Control Studies , Female , Humans , Male , Midwestern United States , Smoking Cessation/methods , Taste , Young Adult
14.
Am J Gastroenterol ; 104(10): 2596-604; quiz 2605, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19550407

ABSTRACT

The use of oral rehydration solution (ORS) has revolutionized the management of acute diarrhea. The implementation of the standard World Health Organization ORS (WHO-ORS) has resulted in decreased mortality associated with acute diarrheal illnesses in children, although in general stool volume and diarrhea durations are not reduced. Decreased morbidity and mortality have occurred because of improved hydration status. Decreased morbidity has also been described in adults who used this therapy. Various modifications to the standard ORS have been derived. These modifications have included hypo-osmolar or hyperosmolar solutions, use of rice-based ORS, zinc supplementation, and the use of amino acids, including glycine, alanine, and glutamine. Some of these variations have been successful, some have not, and others are still under investigation. ORS has been used for travelers' diarrhea and to decrease intravenous (IV) fluid requirements in patients with short bowel syndrome (SBS) who require parenteral nutrition (PN). This paper reviews the standard WHO-ORS and its mechanism of action, followed by more contemporary reduced osmolarity ORS and rice-based ORS in non-cholera diarrhea. Various modifications to improve ORS are also discussed.


Subject(s)
Diarrhea/therapy , Fluid Therapy/methods , Amino Acids/therapeutic use , Animals , Bicarbonates , Clinical Trials as Topic , Diarrhea/mortality , Flavoring Agents/therapeutic use , Glucose , Humans , Lactoferrin/therapeutic use , Muramidase/therapeutic use , Oryza , Osmolar Concentration , Polysaccharides/therapeutic use , Potassium Chloride , Sodium Chloride , Zinc/therapeutic use
15.
Braz Oral Res ; 22(3): 252-7, 2008.
Article in English | MEDLINE | ID: mdl-18949312

ABSTRACT

This study aimed to evaluate the effects of a flavor-containing dentifrice on the formation of volatile sulphur compounds (VSCs) in morning bad breath. A two-step, blinded, crossover, randomized study was carried out in 50 dental students with a healthy periodontium divided into two experimental groups: flavor-containing dentifrice (test) and non-flavor-containing dentifrice (control). The volunteers received the designated dentifrice and a new toothbrush for a 3 X/day brushing regimen for 2 periods of 30 days. A seven-day washout interval was used between the periods. The assessed parameters were: plaque index (PI), gingival index (GI), organoleptic breath scores (ORG), VSC levels (as measured by a portable sulphide monitor) before (H1) and after (H2) cleaning of the tongue, tongue coating (TC) wet weight and BANA test from TC samples. The intra-group analysis showed a decrease in ORG, from 3 to 2, after 30 days for the test group (p < 0.05). The inter-group analysis showed lower values in ORG, H1 and H2 for the test group (p < 0.05). There was no difference between the amount of TC between groups and the presence of flavor also did not interfere in the BANA results between groups (p > 0.05). These findings suggest that a flavor-containing dentifrice seems to prevent VSCs formation in morning bad breath regardless of the amount of TC in periodontally healthy subjects.


Subject(s)
Dentifrices/therapeutic use , Flavoring Agents/therapeutic use , Halitosis/prevention & control , Sulfur Compounds/analysis , Adolescent , Adult , Bacteria/drug effects , Cross-Over Studies , Dental Plaque/prevention & control , Dental Plaque Index , Dentifrices/chemistry , Double-Blind Method , Female , Halitosis/microbiology , Humans , Male , Saliva/microbiology , Sulfur Compounds/metabolism , Tongue/microbiology , Toothbrushing , Young Adult
16.
Braz. oral res ; 22(3): 252-257, 2008. tab
Article in English | LILACS | ID: lil-495601

ABSTRACT

This study aimed to evaluate the effects of a flavor-containing dentifrice on the formation of volatile sulphur compounds (VSCs) in morning bad breath. A two-step, blinded, crossover, randomized study was carried out in 50 dental students with a healthy periodontium divided into two experimental groups: flavor-containing dentifrice (test) and non-flavor-containing dentifrice (control). The volunteers received the designated dentifrice and a new toothbrush for a 3 X/day brushing regimen for 2 periods of 30 days. A seven-day washout interval was used between the periods. The assessed parameters were: plaque index (PI), gingival index (GI), organoleptic breath scores (ORG), VSC levels (as measured by a portable sulphide monitor) before (H1) and after (H2) cleaning of the tongue, tongue coating (TC) wet weight and BANA test from TC samples. The intra-group analysis showed a decrease in ORG, from 3 to 2, after 30 days for the test group (p < 0.05). The inter-group analysis showed lower values in ORG, H1 and H2 for the test group (p < 0.05). There was no difference between the amount of TC between groups and the presence of flavor also did not interfere in the BANA results between groups (p > 0.05). These findings suggest that a flavor-containing dentifrice seems to prevent VSCs formation in morning bad breath regardless of the amount of TC in periodontally healthy subjects.


Subject(s)
Adolescent , Adult , Female , Humans , Male , Young Adult , Dentifrices/therapeutic use , Flavoring Agents/therapeutic use , Halitosis/prevention & control , Sulfur Compounds/analysis , Bacteria/drug effects , Cross-Over Studies , Dental Plaque Index , Double-Blind Method , Dental Plaque/prevention & control , Dentifrices/chemistry , Halitosis/microbiology , Saliva/microbiology , Sulfur Compounds/metabolism , Toothbrushing , Tongue/microbiology , Young Adult
17.
J Nutr Health Aging ; 11(5): 439-54, 2007.
Article in English | MEDLINE | ID: mdl-17657366

ABSTRACT

BACKGROUND: Abnormalities in taste and smell functioning occur with elevated frequency in both older adults and patients with cancer. With the predicted increase in both of these populations in the coming decades, it is imperative to evaluate potential interventions that are designed to help older cancer patients compensate for the additive burden of this disease and its treatment on age-related taste and smell losses. OBJECTIVE: The purpose of the current study was to determine if providing instruction and products for flavor enhancement of foods to elderly cancer patients in addition to nutritional information would improve their nutritional status, and, by extension, functional and immune status as well as quality of life. DESIGN: One hundred and seven subjects enrolled in the study. Fifty-four subjects were in the experimental group that received flavor enhancement plus nutritional information; fifty-three control subjects received only nutritional information. Subjects were evaluated 1 month, 3 months, and 8 months after beginning chemotherapy. At every session, subjects completed taste and smell assessments as well as questionnaires related to nutritional status, activities of daily living, and quality of life. Blood samples were also obtained to determine immune parameters. RESULTS: At the eight-month time point, experimental subjects had better scores on the mini nutritional assessment (MNA) and the physical function assessment of the quality of life questionnaire. Also at eight months, self-reported taste and smell perception for experimental subjects was better than that of controls as well as better than at earlier time points. Tests that assessed quantity and quality of food intake, as well as a number of immune parameters declined over time and did not differ significantly between groups. CONCLUSION: The combination of flavor enhancement, chemosensory education, and nutritional information for elderly cancer patients improved their nutritional assessment on the MNA and physical function over time. On the whole, experimental subjects perceived themselves to be better functioning at eight months than did their control counterparts.


Subject(s)
Antineoplastic Agents/adverse effects , Flavoring Agents/therapeutic use , Nutritional Status , Olfaction Disorders/therapy , Taste Disorders/therapy , Activities of Daily Living , Aged , Aged, 80 and over , Breast Neoplasms/drug therapy , Female , Humans , Lung Neoplasms/drug therapy , Male , Malnutrition/chemically induced , Malnutrition/therapy , Middle Aged , Nutrition Assessment , Olfaction Disorders/chemically induced , Quality of Life , Smell/physiology , Taste/physiology , Taste Disorders/chemically induced , Treatment Outcome
19.
Thromb Res ; 119(3): 337-42, 2007.
Article in English | MEDLINE | ID: mdl-16626787

ABSTRACT

INTRODUCTION: Cinnamaldehyde (CA) has been reported to inhibit in vitro aggregation in human and rabbit platelets; however, little is known about the antithrombotic activities of CA in vivo. MATERIALS AND METHODS: We tested the effects of CA on collagen- or thrombin-induced aggregation of rat platelets in vitro. Hemorrhage and coagulation times of mice treated with CA by the tail-cutting or slide method were measured. We also tested the life-saving effects of CA on experimental models of thrombosis in mice and rats. The anti-platelet effects of CA were examined in rats. RESULTS: CA inhibited collagen- and thrombin-induced platelet aggregation in vitro in a concentration-dependent manner. In mice, CA administration (250, 500 mg/kg orally and 50, 100 mg/kg i.p.) markedly prolonged hemorrhage and coagulation times and effectively reduced the mortality rate of collagen-epinephrine-induced acute pulmonary thromboembolism. In an arteriovenous shunt thrombosis rat model, the CA administration (250, 500 mg/kg orally and 50, 100 mg/kg i.p.) for 10 days dose-dependently decreased thrombus weight. Administration of CA also significantly inhibited collagen-induced platelet aggregation in the rat platelet-rich plasma (PRP). CONCLUSIONS: The results demonstrate that CA may be a promising antithrombotic agent, and its antithrombotic activity may be due to anti-platelet aggregation activity in vitro and in vivo.


Subject(s)
Acrolein/analogs & derivatives , Platelet Aggregation Inhibitors/pharmacology , Platelet Aggregation/drug effects , Pulmonary Embolism/drug therapy , Thrombosis/drug therapy , Acrolein/pharmacology , Acrolein/therapeutic use , Animals , Bleeding Time , Collagen/toxicity , Dose-Response Relationship, Drug , Flavoring Agents/pharmacology , Flavoring Agents/therapeutic use , Humans , Mice , Mice, Inbred BALB C , Platelet Aggregation Inhibitors/therapeutic use , Platelet-Rich Plasma , Pulmonary Embolism/chemically induced , Pulmonary Embolism/metabolism , Rabbits , Rats , Rats, Sprague-Dawley , Thrombosis/chemically induced , Thrombosis/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...